Cholestatic hepatitis is a rare complication of acute Epstein-Barr virus (EBV) infection. Here, we presented a case of acute cholestatic hepatitis secondary to acute infectious mononucleosis, who presented with complaints of abdominal pain, yellowing of the eyes and body, itching, widespread body pain, fever, nausea and vomiting. It was emphasized that EBV infection should also be considered in the differential diagnosis of cholestatic hepatitis etiology.

Background/Objectives: Carbapenem-resistant Klebsiella spp. (CRK) causes healthcare-associated infections with high mortality. This study evaluated the clinical outcomes of ceftazidime–avibactam (CZA) therapy in CRK infections. Methods: Patients hospitalized in a tertiary care hospital in Türkiye between June 2021 and December 2022 with CRK-positive cultures, CZA susceptibility, and ≥72 h of CZA treatment were retrospectively analyzed. Results: Ninety-nine patients (61.6% male; mean age 63.7 ± 17.5 years) were included, 89.9% of whom were treated in the intensive care unit (ICU). Hypertension (29.3%), diabetes (28.3%), and malignancy (26.3%) were the most frequent comorbidities. The main infection types were bloodstream infection (56.6%) and ventilator-associated pneumonia (29.3%). CZA was used as monotherapy in 49.5%, and in combination in 50.5% of cases. The mean treatment duration was 13.2 ± 6.3 days. Clinical improvement occurred at 3.4 ± 1.2 days and microbiological eradication at 4.7 ± 2.1 days. Treatment success was achieved in 76.8% of patients, while 30- and 90-day mortality rates were 48.5% and 72.7%, respectively. Only treatment duration significantly affected clinical outcome (p < 0.001). Conclusions: CZA demonstrates favorable outcomes in CRK infections, with no significant difference between monotherapy and combination therapy. These findings support the use of CZA as an effective treatment option for severe CRK infections in real-world clinical settings and may help guide antimicrobial stewardship strategies in high-risk hospitalized patients.

Brucellosis is one of the most common zoonotic diseases in the world and it can affect many systems. Rarely, central nervous system involvement, which is a

Introduction: This study evaluated Bone Mineral Density (BMD) and examined the associations of serum Receptor Activator of Nuclear factor kappa-B Ligand (RANKL), Osteo-protegerin (OPG), and the RANKL/OPG ratio with Dual-energy X-ray Absorptiometry (DXA) findings and clinical parameters in people living with HIV (PLWH) receiving Antiretroviral Ther-apy (ART). Methods: In this prospective cross-sectional study, adults living with HIV were consecutively recruited at a tertiary care center. Participants underwent DXA, measurement of serum RANKL and OPG levels, and routine biochemical and hematological testing. Clinical and laboratory var-iables were compared according to BMD status, and multivariable linear regression analyses were performed to identify factors associated with RANKL, OPG, and the RANKL/OPG ratio. Results: Low BMD was identified in 20 participants (25.0%), including 14 (17.5%) at the femoral neck and 12 (15.0%) at the lumbar spine. Participants with low BMD were older than those with normal BMD (median 54.0 vs 35.0 years, p = 0.017). Serum RANKL, OPG, and the RANKL/OPG ratio did not differ significantly according to BMD status. In multivariable models, hemoglobin and age were independently and inversely associated with the RANKL/OPG ratio (p = 0.028 and p = 0.041, respectively), whereas age and neutrophil percentage were independently and inversely associated with serum RANKL (p = 0.001 and p = 0.048, respectively) and OPG levels (p = 0.002 and p = 0.023, respectively). Discussion: These findings suggest that circulating RANKL and OPG may not adequately reflect DXA-derived skeletal status in ART-treated PLWH and may be influenced by broader systemic, inflammatory, and hematologic factors. Conclusion: Direct densitometric assessment remains central to skeletal evaluation in PLWH re-ceiving ART.